Obesity is a global health crisis with profound clinical and societal consequences, contributing to increased risks of chronic illness and related mortality.1 Despite being recognised as a disease by ...

On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company. Novo Nordisk (NYSE: NVO) stock ...

By Purvi Agarwal and Sanchayaita Roy (Reuters) -European shares climbed on Monday, recouping some of last week's losses as ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Recursion Pharmaceuticals ( RXRX -5.13%) is not the most famous artificial intelligence (AI) stock on the market, but the ...